Скачать с ютуб Talking PAH: Novel Therapies for Pulmonary Arterial Hypertension в хорошем качестве

Talking PAH: Novel Therapies for Pulmonary Arterial Hypertension

AMA/ANCC/ACPE Activity Archive Pulmonary arterial hypertension (PAH) is a debilitating and progressive disease characterized by pulmonary artery vasoconstriction and vascular remodeling leading to elevation of pulmonary arterial pressures and pulmonary vascular resistance. Current PAH-specific therapies have significantly improved the outlook for patients by improving functional capacity, pulmonary hemodynamics and reducing hospitalization. PAH remains an incurable disease necessitating further research and treatment options. This webcast provides an update on novel advances in pharmacological therapy in PAH. This activity will focus on several important aspects of PAH management including a discussion of clinical trial data on emerging therapeutics for the management of PAH; and a review of strategies to optimize outcomes for patients with PAH. FACULTY Mardi Gomberg Maitland, MD, MSc Director of Pulmonary Hypertension George Washington University School of Medicine and Health Sciences Marc Humbert, MD, PhD Professor of Medicine, University Paris-Saclay Department of Respiratory Medicine, Hopital Bicetre Aaron B. Waxman, MD, PhD Executive Director Center for Pulmonary Heart Disease Review the activity at https://bit.ly/3wtctCs and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation. This activity is provided in collaboration with Rush University Medical Center and Practice Point Communications. Supported by an independent educational grant from Acceleron Pharma Inc.